Nervgen Pharma reported net income of -$21.12M for the quarter ended Jun 2026. This income statement covers 6 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2024 | Mar2025 | Jun2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 70.33M | 79.65M | ||||
| Operating items | ||||||
| Research & DevelopmentR&D | 2.19M | 1.96M | 3.55M | 5.71M | ||
| Selling, General & AdministrativeSG&A | 2.01M | 2.71M | 1.95M | 3.11M | ||
| Other Operating ExpensesOther Opex | 0.00 | |||||
| Operating ExpensesOpex | 4.21M | 4.67M | 5.49M | 8.82M | ||
| Non-operating items | ||||||
| Interest & Investment IncomeInt & Inv Inc | 0.08M | -0.06M | -0.08M | -0.13M | ||
| Other Non Operating IncomeOther Non Op Inc. | 0.01M | 0.02M | -0.02M | -1.55M | ||
| Net income details | ||||||
| Profit After TaxPAT | 2.75M | -6.57M | -1.22M | -21.12M | ||
| Net Income towards Common StockholdersNet Income | -2.75M | -1.22M | ||||
| Additional items | ||||||
| EPS (Basic) | -0.04 | -0.02 | ||||
| EPS (Diluted) | -0.04 | -0.02 | ||||
| Shares Outstanding | 67.32M | 67.32M | 67.32M | 72.33M | 72.33M | 72.33M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 67.32M | 67.32M | 67.32M | 72.33M | 72.33M | 72.33M |